



## Publications – Dr Sandra Prior

**Prior S**, Hufton SE, Fox B, Dougall T, Rigsby P, Bristow A. (2017) [International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab](#). MAbs. 2017 Oct 6:1-14. doi: 10.1080/19420862.2017.1386824

Salazar-Fontana, L.I, Desai, D.D, Khan, T.A., Pillutla, R.C, **Prior, S.**, Ramakrishnan, R., Schneider J. and Joseph, A. (2017) Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development. AAPS J 2017 Mar 12;19(2):377-385. DOI: 10.1208/s12248-016-0030-z

Cheung, G.Y.C., Kelly, S. M., Jess, T.J., **Prior, S.**, Price, N.C., Parton, R. and Coote, J.G. 2009. Functional and structural studies on different forms of the adenylate cyclase toxin of *Bordetella pertussis*. Microb. Pathog. 46:36-42.

Gamazo, C., **Prior, S.**, Lecároz, C., Vitas, A.I., Campanero, Pérez G, González, D. and Blanco-Prieto, M.J. 2007. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections. Expert Opin Drug Deliv, 4 (6):677-88

Xing, D., **Prior, S.**, Corbel, M.J., Parton, R. and Coote, J.G. 2006. Effect of different forms of adenylate cyclase toxin of *Bordetella pertussis* on protection afforded by an acellular pertussis vaccine in a murine model. Infection and Immunity, 74 (12) 6797-6805

Gamazo, C., Blanco-Prieto, M.J., Espuelas, S., Lecároz, M.C., **Prior, S.**, Estevan, M. and Irache, J.M. 2007. Applications of particulate drug delivery systems in the control of an intracellular bacterial pathogen. In: M.N.V. Ravi Kumar (ed) Handbook of Particulate Drug Delivery. American Scientific Publishers, USA ISBN 158883123X

Cheung, G.Y.C., Xing, D., **Prior, S.**, Corbel, M.J., Parton, R. and Coote, J.G. 2006. Effect of different forms of adenylate cyclase toxin of *Bordetella pertussis* on protection afforded by an acellular pertussis vaccine in a murine model. Infection and Immunity, 74 (12) 6797-6805

**Prior, S.**, Fleck, R.A., Gillett, M., Rigsby, P.R., Corbel, M.J., Stacey, G.N. and Xing, D.K.L. 2006. Evaluation of adenylate cyclase toxin constructs from *Bordetella pertussis* as candidate vaccine components in and in vitro model of complement-dependent intraphagocytic killing. Vaccine, 24 (22), 4794-4803.

Gamazo, C., Lecároz, C., **Prior, S.**, Vitas, A.I., Campanero, M.A., Irache, J.M. and Blanco-Prieto, M.J. 2006. Chemical and biological factors in the control of *Brucella* and brucellosis. Current Drug Delivery, 3 (4) 359-365.

**Prior, S.**, Corbel, M.J. and Xing, D.K.L. 2005. Development of an approach for the laboratory toxicological evaluation of *Bordetella pertussis* adenylate cyclase genetic toxoid constructs as multipurpose vaccines. Human Vaccines, 1 (4), 151-159.



**Prior, S.**, Gander, B., Irache, J.M. and Gamazo, C. 2005. Gentamicin-loaded microspheres for the treatment of experimental *Brucella abortus* infection in mice. *J. Antimicrob. Chemother.* 55, 1032-1036

**Prior, S.**, Gander, B., Lecároz, C., Irache, J.M. and Gamazo, C. 2004. Gentamicin-loaded microspheres for reducing intracellular *Brucella abortus* from infected monocytes. *J. Antimicrob. Chemother.* 53, 981-988

Gamazo, C., Blanco-Prieto, M.J., Lecároz, M.C., Vitas, A.I., Gander, B., Irache, J.M. and **Prior, S.** 2004. New therapeutic approaches for the treatment of *Brucella* infections: gentamicin entrapment into drug delivery systems. *Current Medicinal Chemistry Anti-Infective Agents* 3(1), 43-56

**Prior, S.**, Xing, D., Auda, G. and Corbel, M. 2002. Evaluation of the toxicity of recombinant *Bordetella pertussis* adenylate cyclase toxin preparations. In: Brown, F., Hendriksen, C. Sesardic, D. (eds): *Advancing Science and Elimination of the use of laboratory animals for development and control of vaccines and hormones.* *Dev. Biol. Basel*, Karger, vol 111, 117-127

Xing, D., Canthaboo, C., Douglas-Bardsley, A., Yuen, CT., **Prior, S.**, Liu, Y. and Corbel, M. 2002. Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines. In: Brown, F., Hendriksen, C. Sesardic, D. (eds): *Advancing Science and Elimination of the use of laboratory animals for development and control of vaccines and hormones.* *Dev. Biol. Basel*, Karger, vol 111, 57-68

**Prior, S.**, Gander, B., Blarer, N., Merkle, H.P., Subirá, M.L., Irache, J.M. and Gamazo, C. 2002. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. *Eur. J. Pharm. Sci.* 15, 197-207

Murillo, M., Espuelas, S., **Prior, S.**, Vitas, A.I., Renedo, M.J., Goni, M.M., Irache, J.M. and Gamazo, C. 2001. Controlled liberation of active principles by means of new galenic formulations. *Rev Med Univ Navarra* 45(4), 19-34 (article in Spanish)

**Prior, S.**, Gamazo, C., Irache, J.M., Merkle, H.P. and Gander, B. 2000. Gentamicin sulfate encapsulation in PLA/PLGA microspheres in view of treating intracellular *Brucella* infections. *Int. J. Pharm.* 196, 115-125

Gamazo, C., **Prior, S.**, Irache, J.M., Gander, B., Díaz, R. and Vitas, A.I. 1999. Treatment of experimental brucellosis with gentamicin included in liposomal and microsphere formulations. *Recent Res. Devel. Antimicrob. Agents & Chemother.* 3, 59-82

### WHO publications

**Prior, S.**, Bernard Fox, Thomas Dougall, Peter Rigsby and Simon Hufton (2017). Report on a Collaborative Study for Proposed Candidate 1<sup>st</sup> International Standard for the biological activities of Rituximab. WHO/BS/2017.2309